Dataset related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"

This record contains raw data related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"

Aims: Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5-15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer.

Materials and methods: Data on patients with a maximum of five metastases were collected from three institutions. Concomitant systemic therapy was allowed. End points were the local control of treated metastases, distant progression-free survival (PFS), overall PFS and overall survival.

Results: Data for 82 lesions and 61 patients were included. The primary tumour was located in the bladder in 82% of patients, followed by kidney pelvis (11.5%). The most common treated site was lung (40.2%). Twenty-nine (47.5%) and 14 (23%) patients received systemic therapy before and during SBRT, respectively. The median BED10 value was 78.7 Gy. The median follow-up was 17.2 months. Rates of local control at 1 and 2 years were 92% and 88.9%, respectively, with correlation with systemic therapy before SBRT (hazard ratio 2.62, P = 0.034). Overall PFS at 1 and 2 years was 47.9% and 38.1%, respectively. The number of metastases was a predictive factor (hazard ratio 2.65, P = 0.008). The median overall survival was 25.6 months. Total dose (hazard ratio 0.93, P = 0.003) and BED10 (hazard ratio 0.97, P = 0.006) were correlated with overall survival. No grade ≥2 adverse events were reported.

Conclusions: SBRT represents an effective and safe treatment in metastatic urothelial carcinoma. Prospective randomised trials are necessary to better evaluate the benefit on delaying the onset of new systemic therapies.

本数据集包含与论文《立体定向体部放射治疗在寡转移及寡进展性膀胱癌与其他泌尿上皮恶性肿瘤管理中的应用》相关的原始研究数据。

研究目的：膀胱癌是最常见的泌尿上皮癌类型，发生转移的患者中位总生存期为12.5~15个月。本研究评估了立体定向体部放射治疗（stereotactic body radiation therapy, SBRT）在寡转移泌尿上皮癌管理中的作用。

材料与方法：本研究从三家医疗机构收集了最多存在5处转移灶的患者临床数据，允许同步联合全身治疗。研究终点包括治疗转移灶的局部控制率、远处无进展生存期（progression-free survival, PFS）、总体无进展生存期以及总生存期。

结果：本研究共纳入61例患者的82处转移灶。其中82%的患者原发肿瘤位于膀胱，其次为肾盂（11.5%）。最常见的治疗靶部位为肺部（40.2%）。分别有29例（47.5%）与14例（23%）患者在SBRT治疗前及治疗期间接受了全身治疗。患者接受治疗的中位生物等效剂量BED10为78.7 Gy。中位随访时长为17.2个月。治疗后1年与2年的局部控制率分别为92%与88.9%，且与SBRT前接受全身治疗存在显著相关性（风险比=2.62，P=0.034）。治疗后1年与2年的总体无进展生存率分别为47.9%与38.1%，转移灶数量为其独立预测因素（风险比=2.65，P=0.008）。患者的中位总生存期为25.6个月。总照射剂量（风险比=0.93，P=0.003）与BED10值（风险比=0.97，P=0.006）均与总生存期显著相关。本研究未报告≥2级的不良事件。

结论：立体定向体部放射治疗（SBRT）是转移性泌尿上皮癌的一种安全且有效的治疗手段。未来需开展前瞻性随机对照试验，以进一步明确其在延缓新型全身治疗启用时机方面的临床获益。